

A sigh of relief for babies' tummies:

HiPP ORGANIC COMBIOTIC®
strengthens the gut-lung axis




New data show:
fewer respiratory infections!

Baby: Mathilda, 7 months

Hardly noticed so far, but highly relevant: the gut-lung axis

The gut and lungs interact bidirectionally via the gut microbiota, its metabolic products and the immune system.^{1,2}





A strong intestinal immune system protects the lungs!


New GOLF* III trial shows:

With synbiotic HiPP ORGANIC COMBIOTIC® secretory IgA, a marker for the intestinal immune system, was increased by 38% in faeces after 12 months compared to the control group.³

Significantly fewer lower respiratory tract infections with HiPP ORGANIC COMBIOTIC®

- 50-70% of infants suffer from a lower respiratory tract infection in the first year of life.^{4,5}
- 23 % fewer lower respiratory tract infections with HiPP ORGANIC COMBIOTIC® in the first year of life, compared to the control group³
- incidence comparable between HiPP ORGANIC COMBIOTIC® and breastfed infants (reference group)³



 HiPP ORGANIC COMBIOTIC® is a synbiotic formula providing *Limosilactobacillus fermentum* CECT5716 and GOS for non-breastfed infants.

Well supplied with HiPP ORGANIC COMBIOTIC®

- **Effective support of the gut microbiota** with pre- and probiotics^{6,7}
- **Increased colonisation of the gut** with bifidobacteria and lactobacilli^{6,7}
- **Positive effects** on the intestinal immune system and intestinal environment³
- **Stronger immune system:** lower incidence of lower respiratory^{3,7} and gastrointestinal tract infections^{7,8}

Important information: Breastfeeding is best for babies. Infant formula should only be given upon the advice of paediatricians, midwives or other independent experts.

* GOLF: Prebiotics GOS (galacto-oligosaccharides) and probiotics *L. fermentum* (*Limosilactobacillus fermentum* CECT5716).

1 Enaud et al. Front Cell Infect Microbiol. 2020 Feb; 10:9. **2** Alcazar et al. Lancet Microbe. 2022 Nov; 3(11): e867–e880. **3** Piloquet et al. Efficacy and safety of a synbiotic infant formula for the prevention of respiratory and gastrointestinal infections: A randomized controlled trial. (accepted for publication in AJCN). **4** Ontani et al. BMC Infect Dis 22, 313 (2022). **5** „Respiratorische Synzytial-Virus-Infektionen (RSV)“, RKI-Ratgeber 2024. **6** Lagkouvardos et al. Am J Clin Nutr 2023; 117 (2): 326–339. **7** Maldonado et al. J Pediatr Gastroenterol Nutr 2012; 54(1): 550–61. **8** Gil-Campos et al. Pharmacol Res 2012; 65(2): 231–238.



Scanning the QR-Code will take you directly to the original study by Piloquet et al. 2024